Skip to main content
Therma Bright Inc. logo

Therma Bright Inc. — Investor Relations & Filings

Ticker · THRM ISIN · CA8834262070 LEI · 529900PN7P0GSORO2174 TSXV Manufacturing
Open in API
Filings indexed 525 across all filing types
Latest filing 2022-06-23 Regulatory Filings
Country CA Canada
Listing TSXV THRM

About Therma Bright Inc.

https://www.thermabright.com/

Therma Bright Inc. is a medical technology company that develops, acquires, and markets proprietary diagnostic and medical device technologies for the consumer and institutional healthcare sectors. The company's portfolio addresses key areas including pain management, circulation, diagnostics, and critical care. Core products and development projects include Venowave, a medical device designed to boost circulation and prevent blood clots; the Digital Cough Test (DCT), an AI-powered application developed with AI4LYF for rapid, non-invasive detection of respiratory diseases; and the PREVA™ clot retriever, developed with Inretio for enhanced thrombectomy procedures in ischemic stroke treatment. Furthermore, Therma Bright is advancing inhaled statin therapy in partnership with InVixa for the treatment of COVID-19 pneumonia and Acute Respiratory Distress Syndrome (ARDS).

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2022-06-23 English
News release - English.pdf
Regulatory Filings
2022-06-10 English
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'FORM 51-102F3 MATERIAL CHANGE REPORT' and provides an update on a material change related to Therma Bright Inc.'s FDA EUA application process for a COVID-19 test. It includes a news release dated June 2, 2022, describing the company's progress and expectations regarding the FDA Emergency Use Authorization. The document is a regulatory disclosure about a material change event, not a full financial report, earnings release, or management discussion. It is a formal regulatory filing to inform investors and the market about significant company developments. The form number 51-102F3 corresponds to a material change report under Canadian securities regulations, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other specific categories like earnings, annual report, or capital update. The document length (7443 characters) and content confirm it is a full regulatory announcement rather than a brief report publication announcement or certification.
2022-06-03 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release providing an update on the FDA Emergency Use Authorization (EUA) application process for a COVID-19 rapid antigen test by Therma Bright Inc. It discusses the submission of the EUA application, interactions with FDA officials, and expectations for approval. There are no financial statements, detailed financial data, or regulatory filings such as annual or quarterly reports. The content is an update on a regulatory process and company progress rather than a formal regulatory filing or financial report. It is not a report publication announcement since it does not mention the release or availability of a report, nor is it a certification or legal proceeding. The document fits best as a general regulatory announcement about the company's regulatory status and progress, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous regulatory updates that do not fit other categories.
2022-06-02 English
Form of proxy - English.pdf
Regulatory Filings
2022-05-21 English
News release - English.pdf
Regulatory Filings
2022-05-10 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.